R
Revalia Bio
Why we are redefining organ donation
About Revalia Bio
Revalia Bio, founded in 2021 by Greg Jensen, is a biotechnology company that has developed a platform for ex vivo human organ research. This platform allows for the study of human organs outside the body, which can help to accelerate the development of new drugs and therapies.
Revalia Bio's business model is based on providing contract research services to the biopharmaceutical industry. The company's clients are pharmaceutical and biotechnology companies that are developing new drugs and therapies. Revalia Bio's platform allows these companies to test their products on human organs in a controlled environment, which can help to reduce the time and cost of drug development.
The company's services include target validation, lead optimization, and preclinical development. Revalia Bio's platform can be used to study a wide range of diseases, including cancer, cardiovascular disease, and infectious diseases.
Revalia Bio has raised a total of $12.3 million in funding from a number of investors, including 2048 Ventures and a prominent, undisclosed life sciences investor. The company is headquartered in New Haven, Connecticut.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- New Haven, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 90.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Dec 2025 | $0 | — | Advanced Research Projects Agency for Health - ARPA-H | ↗ |
| SEED✓Equity / VC | Sep 2025 | $15M | $58M | Roger W. Ferguson · America's Frontier Fund · Sierra Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Revalia Bio is 2.7K monthly website visits, down 25% over the last three months. Revalia Bio's team grew 42.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
National Kidney Foundation
America's Frontier Fund
Sierra Ventures
Roger W. Ferguson
Advanced Research Projects Agency for Health - ARPA-H
Other known investors3 additional known investors
Yale University
Connecticut Innovations
Leva Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Revalia Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Revalia Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.